Abstract:
Due to the high efficacy of glucagon-like peptide receptor agonists (GLP-1RAs) and dual mechanism glucose-dependent insulinotropic polypeptide/glucagon-like peptide receptor agonists (GIP/GLP-1RAs) for weight reduction and glycemic control, there is increased utilization for patients with obesity and/or T2DM. Yet, the impact of these medications on dietary intake is less understood. This narrative literature review summarizes clinical studies quantifying and characterizing dietary intake in people with obesity and/or T2DM using GLP-1 or GIP/GLP-1 RA.
Author Bios
SANDRA CHRISTENSEN, MSN, ARNP, FNP-BC, MFOMA, FAANP
Obesity Specialist, Speaker & Author,
Integrative Medical Weight Management
Seattle, WA, USA
Integrative Medical Weight Management
Seattle, WA, USA
KATIE ROBINSON, PHD, MPH, RD, LD, CNSC
Medical Science Liaison Manager
Scientific and Medical Affairs
Abbott Nutrition
Columbus, OH, USA
Scientific and Medical Affairs
Abbott Nutrition
Columbus, OH, USA
SARA THOMAS, PHD, RD
Research Scientist Global Adult Nutrition Science
Abbott Nutrition Division of Abbott
Columbus, OH, USA
Abbott Nutrition Division of Abbott
Columbus, OH, USA
DOMINIQUE R. WILLIAMS, MD, MPH, FOMA, Dipl. ABOM
Adult Nutrition Medical Director
Abbott
Columbus, OH, USA
Abbott
Columbus, OH, USA
attended a live program?
FREQUENTLY ASKED QUESTIONS